

Inhibition of proliferation and apoptosis induced by a Na⁺/H⁺ exchanger-1 (NHE-1) antisense gene on drug-resistant human small cell lung cancer cells

SHUJUN LI^{1*}, PENGTAO BAO^{1*}, ZHIKUI LI¹, HF OUYANG¹, CHANGGUI WU¹ and GUI SHENG QIAN²

¹Department of Respiratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an 710032;

²Department of Respiratory Medicine, Xinqiao Hospital, Third Military Medical University, Chongqi 400037, P.R. China

Received December 23, 2008; Accepted February 17, 2009

DOI: 10.3892/or_00000347

Abstract. The goal of this study was to evaluate the effect of the Na⁺/H⁺ exchanger-1 (NHE-1) antisense gene on drug-resistant human small cell lung cancer (SCLC) cell proliferation and apoptosis. A recombinant NHE-1 antisense gene was transfected into drug-resistant human SCLC H446/CDDP cells. Intracellular pH (pHi) was measured with fluorescence spectrophotometry. Cell proliferation was assayed cytometrically, and expression of the apoptosis gene caspase-3 was assayed using immunohistochemistry. Apoptosis and the cell cycles were imaged using a flow cytometer. pHi decreased significantly in transfected cells compared with control cells transfected with an empty vector (6.86±0.01 and 7.25±0.02, respectively, P<0.01). Cell proliferation began to decrease 48 h after antisense gene transfection, and the expression of the caspase-3 was stronger in transfected cells compared to the control group. The drug resistant exponent was significantly decreased (P<0.01), and there were more cells in G1 in the transfected group compared to the control group (70 and 57%, respectively, P<0.05). The rate of apoptosis in transfected cells was significantly higher than in the control group (12.18±1.86 and 2.37±0.33%, respectively, P<0.01). The NHE-1 antisense gene was able to induce drug-resistant human SCLC H446/CDDP cells to become acidified and apoptotic, which could provide a novel therapy for multi-drug resistance SCLC.

Introduction

Small cell lung cancer (SCLC) is a non-resectable and highly metastatic neoplastic disease, accounting for about 20% of all lung cancers (1). It is particularly aggressive and has a

poor prognosis, with the 5-year survival rate at diagnosis rarely exceeding 10% (2). SCLC is a chemosensitive and radiosensitive disease; chemotherapy for SCLC typically involves a combination of etoposide, doxorubicin, vincristine, paclitaxel, and platinum-based regimens (3-5). First-line combination chemotherapy (with or without regional radiotherapy) induces a positive response in 70% of patients, with 50% of patients showing complete remission (6,7). However, 90% of these complete remission patients relapse with multi-drug resistant tumours, making chemotherapy ineffective (8,9). Multidrug resistance is a serious clinical problem, which often severely limits the effectiveness of cancer chemotherapy (10). Thus, treating SCLC presents a significant clinical challenge.

However, an effective way to treat SCLC multi-drug resistance has been reported (11). NHE-1 can directly interact with other regulatory cellular signaling pathways and is a multifaceted regulator of cell migration, proliferation, and cell death (12-14). The Na⁺/H⁺ exchanger NHE-1 isoform is expressed ubiquitously and plays the crucial role of regulating intracellular pH by catalyzing the exchange of one extracellular sodium ion against one intracellular proton. Maintaining a steady-state intracellular pH during physiological conditions requires the continuous cellular export of acidic equivalents (15,16). Na⁺/H⁺ exchangers (NHE) are membrane transporters that facilitate H⁺ efflux in cells (17).

Indeed, activation of NHE-1 and the resulting cellular alkalinization has been described as a key mechanism for the development and maintenance of tumour cells (18). Tumour cells deficient in NHE activity either fail to grow or show severely retarded growth when implanted in immunodeficient mice (19). Previous studies have provided strong evidence that NHE-1 gene expression was consistent with cell survival (13,20). Moreover, decreased NHE-1 expression led to tumour cell growth arrest, acidification of the intracellular milieu, and sensitization to death triggers (21). Intracellular H⁺ increases, resulting in a pHi less than 7.0, can trigger cell apoptosis (22). Tumour cells rely on increased NHE-1 gene expression in order to strengthen the Na⁺/H⁺ exchange, pump out abnormally high levels of intracellular H⁺, thus preventing the pHi decline and intracellular acidification (19). As a result, NHE-1 gene expression in tumour

Correspondence to: Dr Changgui Wu, Department of Respiratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, P.R. China
E-mail: bao03@163.com

*Contributed equally

Key words: NHE-1, antisense gene, small cell lung cancer, drug resistance

cells may play an important role in protecting them against apoptosis (23). Thus, NHE-1 is a potential target for intervention in multi-drug resistance SCLC.

Cisplatin is one of the most important chemotherapeutic drugs in clinical practice (24). Although its mode of action has been under intensive study since its discovery more than 30 years ago, the exact mechanism has yet to be defined (25,26). Cisplatin-induced multi-drug-resistant lung cancer cell lines are used to gain better understanding of SCLC (27). The resistance cell line NCI-H446/CDDP generated in our center has stable cell biological characteristics and is a reliable multi-drug resistance model of SCLC (28,29).

This study aims to uncover the effect of the NHE-1 antisense gene on the drug-resistant SCLC cell line H446/CDDP and to prove that intra-cellular acidification can inhibit resistant lung cancer cell proliferation and cause apoptosis, with the final goal of finding a novel therapy for multi-drug resistance SCLC.

Materials and methods

Construction of the NHE-1 antisense expression vector pCMV-Script and NHE-1 mRNA quantitative analysis. The primer sequences were 5'-TCAAGCTTCAGTCACTTTCCTCAGC-3' and 5'-CGGATCCAACCACCACGAGTAAGG-3'. The 5' primer had an engineered *Hind*III restriction site, and the 3' primer had an engineered *Bam*HI restriction site. We amplified cDNA from the A549 human lung cancer cell line using conventional PCR. Conditions were 95°C, 3 min, the addition of the Taq enzyme; 94°C, 40 sec, 60°C, 40 sec, 72°C 45 sec, 35 cycles; 72°C 10 min.

Purified PCR products were cut with *Hind*III + *Bam*HI enzymes and then inserted into the pCMV-Script vector (Promega, USA). Successful integration of the plasmid was evaluated by *Hind*III + *Bam*HI double digestion. The construct was sequenced by the Boya Company (Shanghai, China). The plasmid was transformed into competent XL-Blue cells and the plasmid DNA was purified (Promega) and checked using *Hind*III + *Bam*HI digests.

Cell monolayers were grown to the exponential phase of growth, RNA was extracted, and RT-PCR was performed by the afore-mentioned method. Upper primers: 5'-TGACG GTCAGGTCATCACTATCGGCAATGA-3', lower primers: 5'-TTGATCTTCATGGTGTAGGAGCGAGGGCA-3'. We determined the strip integral optical density (indicated by grayscale) in order to measure expression of NHE-1.

Cell transfection. Resistant H446/CDDP SCLC cells were cultured in RPMI-1640 medium (containing 10% FBS) at 37°C in 5% CO₂. The antisense expression vector was transfected into H446/CDDP SCLC cells using a lipid transfection method and called group T. The control group was transfected with an empty vehicle and called group C. Forty-eight hours after transfection, fresh RPMI-1640 medium with 10% FBS and G-418 (final concentration 500 µg • ml⁻¹) was added (30).

Cell pHi. Tumour cells were digested with 0.25% EDTA and 0.01% trypsin, rinsed with Hank's liquid rinse, and made into a single-cell suspension at a density of 5.0x10⁵ cells/ml (31).

Cells (2 ml) were added to 24 test tubes. BCECF-AM (Sigma) was added to a final concentration of 2 µg/ml, and tubes were incubated at 37°C for 30 min in the dark. After the incubation period and a third Hank's liquid rinse, the cells were centrifuged, and the supernatant was discarded. The 24 tubes were divided into eight groups, and 3 ml of KCl buffer at pH 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, or 7.6 was added. Cells were incubated in a 37°C waterbath for 10 min then analysed immediately. Fluorescence intensity was measured at optical wavelengths 440, 495 and 525 nm. Fluorescence intensity was obtained at different pH values in order to calculate standard curves and regression equations.

Group T and group C H446/CDDP cancer cells were made into single-cell suspensions, rinsed twice with Hank's liquid rinse, and then re-suspended in NaCl buffer at a density of 2x10⁶ cells/ml. Three samples were taken from each, BCECF-AM was added, cells were incubated for 30 min at 37°C in the dark, then analyzed immediately. Fluorescence intensity ratios at 495 nm/440 nm were measured, and the average sample pHi was calculated by substituting values into a regression equation.

Cell culture and cell proliferation count. Cells were cultured in DMEM medium supplemented with 10% newborn calf serum (both from Gibco/Invitrogen, NY, USA) in a 37°C incubator with a humidified atmosphere of 5% CO₂-95% O₂ (32). Cells were grown at a density of 1x10⁴ cells/ml. After 24, 48, 72, 96 or 120 h in culture, the number of drug-resistant H446/CDDP cells and recombinant-transfected cells was counted.

MTT assay for H446/CDDP cell drug sensitivity. The number of viable cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay (33). Briefly, the cells were cultured in 96-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) at a density of 1x10⁴ cells/well in the presence of cisplatin, etoposide, vincristine, 5-fluorouracil, or topotecan at the indicated concentrations. Each drug was applied at 5 different concentrations, each 5-fold larger than the next. After a 48-h incubation, MTT (Sigma, St. Louis, MO, USA) dissolved in PBS was added to each well at a final concentration of 5 mg/ml, and the cells were then incubated at 37°C for 4 h. The water-insoluble dark blue formazan crystals that formed during MTT cleavage in actively metabolizing cells were dissolved in DMSO. The optical density was measured at a wavelength of 490 nm with a Bio-Rad 680 microplate reader (Bio-Rad, CA, USA). All experiments were performed in triplicate. IC₅₀, the 50% inhibitory concentration of each drug, was calculated with a logarithmic plot. Inhibitory rate = $(1 - OD_{drug}/OD_{control}) \times 100\%$.

Caspase-3 immunohistochemical analysis. Cells were trypsinised with 0.25% trypsin, plated on coverslips, incubated for 24 h, and then washed three times with Tris-buffered saline (TBS, Sigma). Cells were then fixed with 4% paraformaldehyde for 30 min, dried at 37°C, washed three times with TBS, and equilibrated in TBS containing 0.3% Triton X-100 (Sigma). Endogenous peroxide activity was blocked by treatment with 0.3% H₂O₂ (Sigma) in methanol for 30 min. Cells




Figure 1. Identification and expression analysis of NHE-1. (A) cDNA from human lung cancer A549 cells was used as a template, and conventional PCR methods were used to amplify a 467 bp (including restriction site) DNA fragment. (B) Amplified ligated plasmid included the expected 467 bp length product, showing that the antisense gene vector was successfully transfected into the cell genomes. (C and D) Expression of NHE-1 in cells after transfection with the antisense gene. The transfected group shows significantly less expression than the control group (set β -actin value as 1, $P < 0.01$).

were then treated with 0.1% trypsin in 0.05 M Tris and 0.02 M CaCl_2 (pH 8.0), and non-specific binding was eliminated by blocking with 1.5% normal goat serum (Santa Cruz Biotechnology, USA) and 0.5% bovine serum albumin (BSA) in TBS. The coverslips were then incubated overnight at 4°C with a primary antibody (rabbit polyclonal IgG to caspase-3, diluted 1:200, Santa Cruz Biotechnology) in TBS with 0.5% BSA, followed by incubation with a secondary antibody (HRP-conjugated goat anti-rabbit IgG, Santa Cruz Biotechnology) and then with an avidin/biotin complex (Santa Cruz Biotechnology) in TBS with 0.1% BSA for 1 h. Cells were developed with 0.5% 3,3'-diaminobenzidine (Sigma) in 0.1% H_2O_2 , 0.05 M Tris, and 0.85% NaCl (pH 7.4) for 5 min. Finally, the coverslips were counterstained with Gill's haematoxylin, dehydrated, and mounted with Permount (Sigma). A negative control, in which the primary antibody was omitted, was used to verify the specificity of the immunohistochemical results.

Cell cycle and apoptosis analysis. Cell cycle distribution apoptosis analysis were analysed by flow cytometry as described (34). Briefly, following incubation for 24, 48, 72, 96, or 120 h, cells were trypsinised with 0.25% trypsin (Sigma), counted, centrifuged at 300 g x for 5 min, and fixed in ethanol at 4°C overnight. The cells were then washed and centrifuged. The resulting cell pellets were resuspended in an RNase solution (0.02 mg/ml; Sigma) containing propidium iodide (0.02 mg/ml; Sigma) and incubated at 4°C for 30 min. The DNA content of approximately $1-2 \times 10^5$ stained cells was analysed using a FACScan flow cytometer equipped with the FACStation data management system running CellQuest

software (Becton-Dickinson, San Jose, CA, USA). The results are expressed as a plot of fluorescence intensity versus cell number.

Statistical analysis. All statistical analyses were carried out using SPSS 14.0 statistical software. Data are expressed as the mean \pm the standard error of mean (SEM) of separate experiments. Differences in measured parameters among the groups were analysed by one-factor ANOVA and the least significant difference test. Results with $P \leq 0.05$ were considered statistically significant.

Results

Level of NHE-1 mRNA expression after transfection. The NHE-1 antisense gene sequence was correct as shown by sequencing (Boya Company, China). NHE-1 expression in resistant SCLC H446/CDDP cells after the transfection of the antisense gene was significantly lower than in cells transfected with an empty vector and the gray values was 0.38 ± 0.07 and 0.72 ± 0.09 , respectively ($P < 0.01$) (Fig. 1).

pHi. The pHi in resistant SCLC H446/CDDP cells after antisense gene transfection was markedly lower than in the control group, in which cells were transfected with an empty vector (6.86 ± 0.01 and 7.25 ± 0.02 , respectively, $P < 0.01$).

Cell proliferation. Differences between cell numbers in NHE-1 antisense gene-transfected cells and control cells gradually increased after transfection and became statistically significant at 48 h ($P < 0.01$) (Table I).

Table I. Cell count of H446/CDDP at different time-points.

| Group | 0 | 24 h | 48 h | 72 h | 96 h | 120 h |
|-------|-----------|-----------|------------------------|------------------------|------------------------|------------------------|
| C | 1.00±0.09 | 1.46±0.13 | 2.35±0.26 | 5.58±0.39 | 8.46±0.67 | 12.7±0.78 |
| T | 1.32±0.12 | 1.62±0.15 | 2.85±0.21 ^a | 4.78±0.36 ^a | 6.92±0.55 ^a | 9.03±0.67 ^a |

Cell counts of H446/CDDP were determined at 24, 48, 72, 96, 120 h respectively after NHE-1 antisense gene transfected. The values are shown as the mean ± SEM. ^aP<0.01 compared to the control group [least significant difference (LSD) test by ANOVA].

Table II. Multi-drug resistance index of H446/CDDP cell after transfected NHE-1 antisense gene.

| Drug | Group C | Group N |
|----------------|--------------|---------------------------|
| Cisplatin | 0.7469±0.041 | 0.2971±0.032 ^a |
| Etoposide | 0.5513±0.033 | 0.2379±0.033 ^a |
| Vincristine | 0.4812±0.026 | 0.2921±0.027 ^a |
| 5-Fluorouracil | 2.4718±0.271 | 1.4228±0.156 ^a |
| Topotecan | 0.6216±0.076 | 0.3326±0.057 ^a |

Drug resistance indexes of H446/CDDP cell to cisplatin, etoposide, vincristine, 5-fluorouracil, topotecan after transfected NHE-1 antisense gene were determined respectively. The values are shown as the mean ± SEM. ^aP<0.01 compared to the control group [least significant difference (LSD) test by ANOVA].

Cell drug sensitivity. MTT methods were used to measure the optical density of cells 48 h after transfection. The resistance index to each drug decreased significantly in cells transfected with the NHE-1 antisense gene compared to cells in the control group (P<0.01) (Table II).

Cell cycle and apoptosis. Flow cytometry was used to determine the cell cycle stage. More cells were in the G1 phase in

cells transfected with the NHE-1 antisense gene (G1 phase, 70%; S phase, 17%) than in the control group (G1 phase, 57%; S phase, 30%) (P<0.01) (Fig. 3).

Expression of the pro-apoptotic protein caspase-3 was determined by immunohistochemical analysis. Caspase-3 was present in the cytoplasm and part of the nucleus of NHE-1 antisense transfected cells. In contrast, there was no caspase-3 expression in cells from the control group (Fig. 2).

The apoptosis rate was measured by double-staining flow cytometry analysis. The rate of apoptosis in cells transfected with the NHE-1 antisense gene was 12.18±1.86%, which was significantly higher than the 2.37±0.33% observed in the control cells (P<0.01) (Fig. 3).

Discussion

At present, chemotherapy is still the main treatment for SCLC (35). During and after chemotherapy, cancer cells often become resistant to multiple drugs, which affects the effectiveness of chemotherapy and leads to increased mortality (11,36). The H446/DDP cell line was derived from H446 cells that were made resistant to cisplatin, which is in a category of drugs commonly used in clinical chemotherapy (37). This group includes drugs such as cisplatin, etoposide, vincristine, 5-fluorouracil, and topotecan. The cell cycle of H446/DDP cells is not significantly different from H446 cells, which can reduce errors in the detection of drug




Figure 2. Expression of caspase-3 in cells. Pro-apoptotic gene caspase-3 expression was determined by immunohistochemistry. More yellow-brown positive areas were seen in the cytoplasm of NHE-1 antisense transfected cells, and many nuclei also expressed caspase-3. In contrast, there were more cells in the control, but there was no detectable caspase-3 staining.




Figure 3. Cell cycle and apoptosis 48 h after transfection. (A) Flow cytometry was used to determine the percentage of cells in the different cell cycle phases. More cells were in the G1 phase in cells transfected with the NHE-1 antisense gene than cells in control group ($P < 0.01$). (B) Cell apoptosis rate was measured by double-staining flow cytometry analysis. The rate of apoptosis in cells transfected with the NHE-1 antisense gene was significantly higher than in control group cells ($P < 0.01$).

resistance, so we used the H446/DDP cell line to study experimental MDR *in vitro*.

In this study, we transfected the NHE-1 antisense gene into H446/CDDP cells and found that the NHE-1 level in transfected cells was significantly lower than in cells transfected with an empty vector (control group), suggesting that the transfected NHE-1 antisense gene could effectively reduce or inhibit NHE-1 expression. NHE-1 is an 815 amino acid, 105-110 kDa glycoprotein that is expressed in a wide range of eukaryotic cells (38). In physiological conditions, NHE-1 participates in the regulation of sodium and hydrogen ions, pHi, cell-conditioning capacity, and other important physiological functions by mediating Na^+/H^+ exchange in order to maintain the stability of cells and normal membrane potential (18). NHE-1 is the most important pHi regulator; its expression and activity impacts the stability of cellular pHi, which is the most basic condition required for cell growth (39). When altered, pHi can impact cell growth and function directly, so expression and activity of NHE-1 plays an important role in cell growth (40). An inhibitor of NHE-1 could inhibit cell growth by affecting these processes.

Previous studies have shown that the NHE-1 gene is highly expressed in lung cancer cells. NHE-1 plays an important

role in maintaining lung cancer cells at a neutral or alkaline pHi (39). NHE-1 can prevent tumour cell death induced by acidity, which has significant effects on tumour cell division, growth and proliferation, invasion, and metastasis (41).

This study showed that the pHi in H446/CDDP cells after NHE-1 antisense gene transfection decreased significantly compared with control cells and that the environment around NHE-1 antisense transfected cells was more acidic ($P < 0.01$), which is consistent with previous studies. At the same time, we found that there were fewer cells in the NHE-1 antisense transfected group than in the control group, that the cell doubling time was markedly longer, that cell proliferation was also slower, and that these differences gradually increased as time passed. The number of cells in G1 was significantly increased in the NHE-1 antisense group as compared to the control group 48 h after transfection, while cell number began to have a statistically significant difference ($P < 0.01$), which was most obvious at 120 h. The rate of apoptotic cells after NHE-1 antisense transfection was also larger than in the control group ($P < 0.01$). Immunohistochemical staining showed that the apoptosis gene caspase-3 was expressed strongly in NHE-1 antisense-transfected H446/CDDP cells compared to the control group. This observation suggests

that pH_i in cancer cells plays an important role in cell proliferation and apoptosis; when pH_i decreases to a certain level, it inhibits the cell cycle and induces apoptosis. However, this mechanism should be studied in greater detail.

MTT results showed that the resistance index to cisplatin, 5-fluorouracil, vincristine, etoposide, and topotecan was significantly lower in NHE-1 antisense-transfected H446/CDDP cells than in control cells after 48 h of culture ($P < 0.01$), which implies that the NHE-1 antisense gene effectively induced drug-resistant SCLC H446/CDDP cells to become apoptotic and increased the sensitivity of cells to chemotherapeutic drugs. In other words, inhibition of NHE-1 could effectively induce drug-resistant SCLC to become apoptotic, which might also be related to decreased pH_i in cancer cells.

In conclusion, the above experimental results show that the expression of NHE-1 in drug-resistant SCLC H446/CDDP cells was significantly reduced after cells were transfected with the NHE-1 antisense gene. This transfected NHE-1 antisense gene was able to inhibit the cell cycle, induce cell apoptosis, and reduce chemotherapy drug resistance. Reduced pH_i inside cells may be the mechanism behind this phenomenon, which provides a theoretical basis and a novel way to prevent and treat drug-resistant SCLC.

Acknowledgments

The authors would like to thank Juan Li and Xiao-yan Chen for their excellent technical assistance and Hong Lin for his helpful discussions. This work was funded by the Chinese National Natural Science Foundation, grant number: 30400197.

References

- De Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, van Bochove A, van Tinteren H and Smit EF: Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. *Eur J Cancer* 43: 2345-2350, 2007.
- Fischer B, Marinov M and Arcaro A: Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? *Cancer Treat Rev* 33: 391-406, 2007.
- Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH and Tse C: Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. *Cancer Res* 67: 1176-1183, 2007.
- Hodkinson PS, Mackinnon AC and Sethi T: Extracellular matrix regulation of drug resistance in small-cell lung cancer. *Int J Radiat Biol* 83: 733-741, 2007.
- Rintoul RC and Sethi T: The role of extracellular matrix in small-cell lung cancer. *Lancet Oncol* 2: 437-442, 2001.
- Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW and Cherian MG: Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. *Cancer* 92: 836-842, 2001.
- Tsurutani J, Soda H, Oka M, Suenaga M, Doi S, Nakamura Y, Nakatomi K, Shiozawa K, Amada YY, Kamihira S and Kohno S: Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. *Int J Cancer* 104: 238-242, 2003.
- Triller N, Korosec P, Kern I, Kosnik M and Debeljak A: Multi-drug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naïve patients and in relapsed disease. *Lung Cancer* 54: 235-240, 2006.
- Chan DC, Geraci M and Bunn PA Jr: Anti-growth factor therapy for lung cancer. *Drug Resist Updat* 1: 377-388, 1998.
- Krystal GW, Sulanke G and Litz J: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. *Mol Cancer Ther* 1: 913-922, 2002.
- Ferraldeschi R, Baka S, Jyoti B, Faivre-Finn C, Thatcher N and Lorigan P: Modern management of small-cell lung cancer. *Drugs* 67: 2135-2152, 2007.
- Landau M, Herz K, Padan E and Ben-Tal N: Model structure of the Na⁺/H⁺ exchanger 1 (NHE1): functional and clinical implications. *J Biol Chem* 282: 37854-37863, 2007.
- Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB and Owen CS: Regulation of intracellular pH in human melanoma: potential therapeutic implications. *Mol Cancer Ther* 1: 617-628, 2002.
- Binnie MC, Alexander FE, Heald C and Habib FK: Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. *Prostate* 63: 309-315, 2005.
- Khaled AR, Moor AN, Li A, Kim K, Ferris DK, Muegge K, Fisher RJ, Fliegel L and Durum SK: Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization. *Mol Cell Biol* 21: 7545-7557, 2001.
- Bourguignon LY, Singleton PA, Diedrich F, Stern R and Gilad E: CD44 interaction with Na⁺-H⁺ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. *J Biol Chem* 279: 26991-27007, 2004.
- Grinstein S, Woodside M, Sardet C, Pouyssegur J and Rotin D: Activation of the Na⁺/H⁺ antiporter during cell volume regulation. Evidence for a phosphorylation-independent mechanism. *J Biol Chem* 267: 23823-23828, 1992.
- Tekpli X, Huc L, Lacroix J, Rissel M, Poet M, Noel J, Dimanche-Boitrel MT, Counillon L and Lagadic-Gossman D: Regulation of Na⁺/H⁺ exchanger 1 allosteric balance by its localization in cholesterol- and caveolin-rich membrane microdomains. *J Cell Physiol* 216: 207-220, 2008.
- Pederson SF, Varming C, Christensen ST and Hoffmann EK: Mechanisms of activation of NHE by cell shrinkage and by calyculin A in Ehrlich ascites tumor cells. *J Membr Biol* 189: 67-81, 2002.
- Lagana A, Vadnais J, Le PU, Nguyen TN, Laprade R, Nabi IR and Noel J: Regulation of the formation of tumor cell pseudopodia by the Na⁽⁺⁾/H⁽⁺⁾ exchanger NHE1. *J Cell Sci* 113 (Pt 20): 3649-3662, 2000.
- Zhao R, Oxley D, Smith TS, Follows GA, Green AR and Alexander DR: DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. *PLoS Biol* 5: e1, 2007.
- McLean LA, Roscoe J, Jorgensen NK, Gorin FA and Cala PM: Malignant gliomas display altered pH regulation by NHE1 compared with non-transformed astrocytes. *Am J Physiol* 278: C676-C688, 2000.
- Shen MR, Wilkins RJ, Chou CY and Ellory JC: Anion exchanger isoform 2 operates in parallel with Na⁽⁺⁾/H⁽⁺⁾ exchanger isoform 1 during regulatory volume decrease of human cervical cancer cells. *FEBS Lett* 512: 52-58, 2002.
- Popat S and O'Brien M: Chemotherapy strategies in the treatment of small cell lung cancer. *Anticancer Drugs* 16: 361-372, 2005.
- Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH and Greco FA: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. *J Clin Oncol* 6: 451-456, 1988.
- Evans WK, Feld R, Murray N, *et al.*: The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. *Semin Oncol* 13: 10-16, 1986.
- Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T and Savaraj N: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. *Eur J Pharmacol* 591: 124-127, 2008.
- Ji FY, Qian GS, Qian P, Chen Y, Guo RL, Li SP and Huang GJ: Involvement of bcl-2 in multidrug resistance in human small cell lung cancer cell subline H446/DDP. *Chin J Tuberc Respir Dis* 29: 156-160, 2006.
- Liu LZ, Qian GS and Zhou XD: Expression of a new lung cancer drug resistance-related gene in lung cancer tissues and lung cancer cell strains. *Chin J Cancer* 22: 171-174, 2003.
- Midoux P, Breuzard G, Gomez JP and Pichon C: Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes. *Curr Gene Ther* 8: 335-352, 2008.

31. Pouyssegur J, Franchi A and Pages G: pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. *Novartis Found Symp* 240: 186-196, 2001.
32. Baranes D, Lopez-Garcia JC, Chen M, Bailey CH and Kandel ER: Reconstitution of the hippocampal mossy fiber and associational-commissural pathways in a novel dissociated cell culture system. *Proc Natl Acad Sci USA* 93: 4706-4711, 1996.
33. Denizot F and Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. *J Immunol Methods* 89: 271-277, 1986.
34. Vindelov L and Christensen IJ: An integrated set of methods for routine flow cytometric DNA analysis. *Methods Cell Biol* 33: 127-137, 1990.
35. Fernando JB and Costa AF: Small cell lung cancer - state of the art and future perspectives. *Rev Port Pneumol* 13: 587-604, 2007.
36. Fischer B and Arcaro A: Current status of clinical trials for small cell lung cancer. *Rev Recent Clin Trials* 3: 40-61, 2008.
37. Stordal B and Davey M: Understanding cisplatin resistance using cellular models. *IUBMB Life* 59: 696-699, 2007.
38. Turturro F, Lawson M, Friday E and Welbourne T: Targeting the Na(+)/H(+) exchanger: an old concept with new perspectives in the treatment of hematological malignancies. *Leuk Res* 31: 1449-1450, 2007.
39. Wu GM, Qian GS, Huang GJ, Li SP, Yao W and Lu JY: The effect of Na(+)/H(+) exchanger-1 (NHE-1) antisense expression vector on NHE-1 gene expression in human lung adenocarcinoma cells and its biological significance. *Chin J Tuberc Respir Dis* 27: 191-194, 2004.
40. Glunde K, Dussmann H, Juretschke HP and Leibfritz D: Na(+)/H(+) exchange subtype 1 inhibition during extracellular acidification and hypoxia in glioma cells. *J Neurochem* 80: 36-44, 2002.
41. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M, Alunni-Fabbroni M, Casavola V and Tommasino M: Na⁺/H⁺ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. *FASEB J* 14: 2185-2197, 2000.